Rolofylline

From Self-sufficiency
Jump to: navigation, search
Rolofylline
File:Rolofylline2.png
Systematic (IUPAC) name
8-(Hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione
Legal status
Legal status
Identifiers
CAS Number 136199-02-5
ATC code C03BD (WHO)
PubChem CID 64627
ChemSpider 58188
Chemical data
Formula C20H28N4O2
Molar mass 356.46 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Rolofylline (KW-3902) is an experimental diuretic which acts as a selective adenosine A1 receptor antagonist.[1][2] It was discovered at NovaCardia, Inc. which was purchased by Merck & Co., Inc. in 2007.

Development of rolofylline was terminated on September 1, 2009, after the results of a large clinical trial (PROTECT) showed the drug to be no better than placebo for patients with acute heart failure. Participants given rolofylline did show some improvement in shortness of breath, but the drug did not prevent kidney damage or have any significant effect on overall treatment success. Rolofylline was also associated with a higher incidence of seizures and stroke.[3]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


Receptor ligands
Reuptake inhibitors
ENT inhibitors
VNT inhibitors
 


30px This drug article relating to the cardiovascular system is a stub. You can help ssf by expanding it.
  1. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  2. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  3. ↑ Hughes, Sue (September 1, 2009). "Rolofylline fails to PROTECT in acute heart failure". Medscape. Retrieved 2009-09-02. 
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Rolofylline&oldid=22474"